Skip to main content

Table 3 Annual clinical and parasite responses to dihydroartemisinin-piperaquine treatment of uncomplicated Plasmodium falciparum malaria in Ninh Thuan province, Vietnam

From: Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam

Characteristic

2013 (n = 77)

2014 (n = 56)

2015 (n = 55)

P value*

Parasite clearance time (PCT100)

 Median (IQR) [hours]

36 (24.42)

30 (24.36)

30 (24.36)

0.29

 Proportion with PCT > 72 h

5% (4/77)

7% (4/56)

2% (1/55)

Parasite clearance half- life T1/2 [hours]

 Median (IQR)

1.73 (1.38; 2.05)

1.78 (1.44; 2.36)

2.16 (1.75; 2.73)

0.29

 Geometric mean (95% CI)

1.84 (1.66; 2.03)

1.98 (1.73; 2.27)

2.19 (2.01; 2.39)

 T1/2 > 5 h

5/76 (7%)

5/56 (9%)

1/54 (2%)

Fever clearance time [hours]

 Median (IQR) [hours]

30 (24.54)

18 (12.30)

18 (12.24)

<0.001

Treatment outcome (WHO)

 APCR#

62/77 (81%)

45/56 (80%)

43/55 (78%)

 Early treatment failure

0/77 (0%)

0/56 (0%)

0/55 (0%)

 Clinical treatment failure

3/77 (4%)

1/56 (2%)

0/55 (0%)

 Parasite treatment failure

5/77 (6%)

1/56 (2%)

2/55 (4%)

 Withdrawal

2/77 (3%)

0/56 (0%)

0/55 (0%)

 Loss to follow-up

5/77 (6%)

9/56 (16%)

10/55 (18%)

Risk of failure [PCR-uncorrected]

 Uncorrected Kaplan–Meier estimate (ITT)

11%

4%

4%

0.046

 Uncorrected proportion (per protocol)

8/70 (11%)

2/47 (4%)

2/45 (4%)

0.05

Risk of failure [PCR-corrected]

 Corrected Kaplan–Meier estimate (ITT)

0%

4%

0%

0.81

 Corrected proportion (per protocol)

0/62 (0%)

2/47 (4%)

0/43 (0%)

0.80

 K13-propeller mutation

I543T: 1/77 (1%)

Y493H: 4/77 (5%)

Total 5/77 (6%)

C580Y: 2/56 (3.5%)

Y493H:2/56 (3.5%)

4/56 (7%)

C580Y: 2/55 (4%)

0.53

  1. * P values are based on linear trend tests
  2. APCR adequate clinical and parasitological responses